仑伐替尼治疗肝细胞癌的研究进展

姜仲春; 谷带利; 唐才喜; 谢智钦

doi:10.3969/j.issn.1000-8179.2021.07.222

仑伐替尼治疗肝细胞癌的研究进展

doi: 10.3969/j.issn.1000-8179.2021.07.222

中南大学湘雅医学院附属株洲医院肝胆胰脾外科（湖南省株洲市412007）

基金项目:

湖南省自然科学基金 2017JJ4070

湖南省自然科学青年基金 2020JJ5998

湖南省科技计划项目 2016SK4006

株洲市2019年科技人才托举项目 2019TJ-07

详细信息

作者简介:
姜仲春专业方向为肝癌基础及临床研究。E-mail：3080591413@qq.com

通讯作者:
谢智钦 zhiqin121@126.com

计量
- 文章访问数: 647
- HTML全文浏览量: 38
- PDF下载量: 72
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-02
- 刊出日期: 2021-04-15

Advances of lenvatinib in the treatment of hepatocellular carcinoma

Department of Hepatobiliary and Pancreatic Surgery, Zhuzhou Hospital Affiliated to Xiangya School of Medicinel, Zhuzhou 412007, China

Funds:

the Natural Science Foundation of Hunan Province 2017JJ4070

the Natural Science Youth Foundation of Hunan Province 2020JJ5998

the Science and Technology Plan Project of Hunan Province 2016SK4006

the 2019 Zhuzhou Science And Technology Talents Promotion Project 2019TJ-07

More Information

Corresponding author: Zhiqin Xie; E-mail: zhiqin121@126.com

摘要

摘要: 肝细胞癌（hepatocellular carcinoma，HCC）是严重威胁人类生命健康的疾病之一，其发病率和死亡率逐年上升，具有发展迅速、高侵袭性和高复发性等特点。大多数患者确诊时已是进展期，而靶向治疗作为进展期肝癌的主要治疗策略，已广泛应用于临床。以往该类患者的一线治疗药物仅有索拉菲尼，但其不良反应大，肿瘤应答率低，对乙型肝炎病毒（hepatitis B virus，HBV）阳性患者的总生存率并无明显改善。近年来，新的靶向治疗药物仑伐替尼在肝癌的治疗研究中取得了良好的疗效，成为继索拉菲尼后治疗进展期肝癌的第2个一线药物。本文就仑伐替尼在治疗HCC中的研究进展进行综述。
- 仑伐替尼 /
- 肝细胞癌 /
- 治疗
Abstract: Hepatocellular carcinoma (HCC) is one of the disease that threaten human life and health, and its morbidity and mortality are increasing annually. It has the characteristics of rapid development, high invasiveness, and a high recurrence rate. Most patients present with advanced stage disease at the time of diagnosis, and targeted therapy is the main treatment strategy for advanced HCC in clinical practice. Sorafenib, which was once the only first-line therapeutic agent for unresectable HCC patients, has significant side effects, a low tumor response rate, and does not improve the overall survival of hepatitis B virus-positive patients. In recent years, a new targeted drug, lenvatinib, has been reported to show good efficacy in the treatment of HCC and has become the second first-line drug after sorafenib. In this article, we review the progress of research on the use of lenvatinib in the treatment of HCC.
- lenvatinib /
- hepatocellular carcinoma (HCC) /
- treatment

HTML全文

参考文献(37)

[1]	Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. doi: 10.1016/S0140-6736(18)30010-2
[2]	曹毛毛, 陈万青. 中国恶性肿瘤流行情况及防控现状[J]. 中国肿瘤临床, 2019, 46(3): 145-149. doi: 10.3969/j.issn.1000-8179.2019.03.283
[3]	Jackson R, Psarelli EE, Berhane S, et al. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase Ⅲ trials[J]. J Clin Oncol, 2017, 35(6): 622-628. doi: 10.1200/JCO.2016.69.5197
[4]	汤剑秋, 汤松, 朱益忠, 等. 乐伐替尼的合成[J]. 中国医药工业杂志, 2018, 49(6): 753-755. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHOU201806007.htm
[5]	王凌霄, 肖典, 周辛波. 口服多靶点酪氨酸激酶抑制剂-乐伐替尼[J]. 临床药物治疗杂志, 2015, 13(5): 11-14. doi: 10.3969/j.issn.1672-3384.2015.05.003
[6]	Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage[J]. Vascular cell, 2014, 6(1): 18. doi: 10.1186/2045-824X-6-18
[7]	Boss DS, Glen H, Beijnen JH, et al. A phaseⅠstudy of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours[J]. Br J Cancer, 2012, 106(10): 1598-1604. doi: 10.1038/bjc.2012.154
[8]	Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models[J]. J Thyroid Res, 2014, 2014: 1-13.
[9]	Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in firstline treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. doi: 10.1016/S0140-6736(18)30207-1
[10]	Nair A, Reece K, Donoghue MB, et al. FDA supplemental approval summary: lenvatinib for the treatment of unresectable hepatocellular carcinoma[J]. Oncologist, 2020, 26(3): e484-e494.
[11]	Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1186. doi: 10.1056/NEJM197111182852108
[12]	Ivy SP, Kaufman BM, Wick JY. An overview of small-molecule inhibitors of VEGFR signaling[J]. Nat Rev Clin Oncol, 2009, 6(10): 569-579. doi: 10.1038/nrclinonc.2009.130
[13]	Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity[J]. Nat Rev Cancer, 2008, 8(8): 579-591. doi: 10.1038/nrc2403
[14]	Kaseb AO, Hanbali A, Cotant M, et al. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature[J]. Cancer, 2009, 115(21): 4895-4906. doi: 10.1002/cncr.24537
[15]	Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res, 2012, 18(8): 2290-2300. doi: 10.1158/1078-0432.CCR-11-2175
[16]	Park SA, Jeong MS, Ha K, et al. Structure and function of vascular endothelial growth factor and its receptor system[J]. BMB Rep, 2018, 51(2): 73-78. doi: 10.5483/BMBRep.2018.51.2.233
[17]	Matsuki M, Hoshi T, Yamamoto Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models[J]. Cancer Med, 2018, 7(6): 2641-2653. doi: 10.1002/cam4.1517
[18]	Ma YC, Yang JY, Yan LN. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a metaanalysis[J]. Eur J Gastroenterol Hepatol, 2013, 25(9): 1007-1016. doi: 10.1097/MEG.0b013e32836019d8
[19]	Maehara O, Sato F, Natsuizaka M, et al. A pivotal role of Kruppellike factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma[J]. Cancer Biol Ther, 2015, 16(10): 1453-1461. doi: 10.1080/15384047.2015.1070992
[20]	Schulze K, Gasch C, Staufer K, et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma[J]. Int J Cancer, 2013, 133(9): 2165-2171. doi: 10.1002/ijc.28230
[21]	Yang XR, Xu Y, Yu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma[J]. Gut, 2010, 59 (7): 953-962. doi: 10.1136/gut.2008.176271
[22]	Shigesawa T, Maehara O, Suda G, et al. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR 1-3 signaling, but not FGFR4 signaling[J]. Carcinogenesis, 2020, 42(1): 58-69.
[23]	Zhang Q, Liu H, Wang H, et al. Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells[J]. Am J Cancer Res, 2019, 9(7): 1382-1385.
[24]	Ikeda M, Okusaka T, Mitsunaga S, et al. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res, 2016, 22(6): 1385-1394. doi: 10.1158/1078-0432.CCR-15-1354
[25]	Furuse J, Ishii H, Nakachi K, et al. Phase Ⅰstudy of sorafenib in Japanese patients with hepatocellular carcinoma[J]. Cancer Sci, 2008, 99(1): 159-165.
[26]	Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J]. J Gastroenterol, 2017, 52(4): 512-519. doi: 10.1007/s00535-016-1263-4
[27]	Abou-Alfa GK, Blanc JF, Miles S, et al. PhaseⅡ study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma[J]. Oncologist, 2017, 22(7): 765-780.
[28]	Park J, Cho J, Lim JH, et al. Relative efficacy of systemic treatments for patients with advanced hepatocellular carcinoma according to viral status: a systematic review and network meta-analysis[J]. Target Oncol, 2019, 14(4): 395-403. doi: 10.1007/s11523-019-00651-7
[29]	袁冰, 王燕, 张金龙, 等. 仑伐替尼治疗经肝动脉化疗栓塞术无效的中晚期肝细胞癌患者的临床观察[J]. 中华医学杂志, 2020, 100(11): 833-836. doi: 10.3760/cma.j.cn112137-20190818-01832
[30]	Kudo M. Extremely high objective response rate of lenvatinib: its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma[J]. Liver Cancer, 2018, 7(3): 215-224. doi: 10.1159/000492533
[31]	Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond upto-seven criteria and child-pugh a liver function: a proof-of-concept study[J]. Cancers (Basel), 2019, 11(8): 1084. doi: 10.3390/cancers11081084
[32]	Matsuki M, Adachi Y, Ozawa Y, et al. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus[J]. Cancer Science, 2017, 108(4): 763- 771. doi: 10.1111/cas.13169
[33]	Finn RS, Ikeda M, Zhu AX, et al. Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma [J]. J Clin Oncol, 2020, 38(26): 2960-2970. doi: 10.1200/JCO.20.00808
[34]	Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma[J]. Cancer Treat Rev, 2019, 77: 20-28. doi: 10.1016/j.ctrv.2019.05.004
[35]	Hirooka M, Ochi H, Hiraoka A, et al. Destructive thyroiditis induced by lenvatinib in three patients with hepatocellular carcinoma[J]. Intern Med, 2019, 58(6): 791-795. doi: 10.2169/internalmedicine.1874-18
[36]	Sato- Sano M, Cury-Martins J, Macarenco R, et al. Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib[J]. J Dtsch Dermatol Ges, 2018, 16(12): 1486-1489.
[37]	Suzuki N, Tajiri K, Futsukaichi Y, et al. Perforation of the small intestine after introduction of lenvatinib in a patient with advanced hepatocellular carcinoma[J]. Case Rep Gastroenterol, 2020, 14(1): 63-69. doi: 10.1159/000505774